drugset / Trial / NCT03343600
Imatinib for Cytomegalovirus Prophylaxis and Treatment After Allogeneic Hematopoietic Stem Cell Transplantation
Phase 2
Terminated
5 enrolled
National Taiwan University Hospital
Far Eastern Memorial Hospital · collabHualien Tzu Chi General Hospital · collabNational Cheng-Kung University Hospital · collabTri-Service General Hospital (TSGH) · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
This study aim at examining whether blocking platelet-derived growth factor receptor-α by imatinib lowers the risk of post-allogeneic hematopoietic stem cell transplantation CMV infection.
Timeline
- Start
- 2017-11-09
- Primary completion
- 2019-08-31
- Completion
- 2019-08-31
Outcome
Outcome not reported
Stopped (Enrollment): “The trial is terminated due to the extremely low recruitment rate.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Imatinib | Small molecule | 200 mg | — |